Preface Preface Author Cloud Assistant Antibody-drug conjugates (ADCs) are a class of emerging drugs that combine the advantages of both antibodies and small molecule toxins. Compared to traditional cytotoxic drugs, ADCs have the advantages of strong targeting and fewer side effects, making them promising in the field of tumor therapy. To date, 11 ADC drugs … Read more
Introduction Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies that target specific antigens with small molecule cytotoxic drugs through linkers, combining the powerful killing effect of traditional small molecule chemotherapy with the tumor targeting ability of antibody drugs.ADCs consist of three main components: the antibody responsible for selectively recognizing cancer cell surface antigens, the … Read more
An Analog-to-Digital Converter (ADC) is primarily used to convert continuously transmitted analog signals into digital signals, facilitating rapid processing and analysis of transmitted information by digital systems (such as CPUs and MCUs). Generally speaking, the different quantization mechanisms of ADCs are one of the key factors determining the complexity and performance of ADC design, as … Read more
Introduction Antibody-drug conjugates (ADCs) typically consist of: highly specific and high-affinity antibodies, stable linkers, and potent small-molecule cytotoxic drugs1. The key to the development of ADCs lies in the selection of targets, antibodies, cytotoxic payloads, linkers, and the conjugation method. Among these, the conjugation method of ADCs directly determines the drug-to-antibody ratio (DAR), the distribution … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxicity and side effects of traditional small molecule drugs while improving overall therapeutic efficiency. Currently, there are 13 … Read more
*For reference by medical professionals only Antibody-drug conjugates (ADCs) have become a new hotspot in the field of anti-tumor therapy, with explorations in the treatment of breast cancer, lung cancer, gastric cancer, colorectal cancer, and other types of cancer. With the approval and clinical entry of drugs such as Trastuzumab Deruxtecan, Ado-trastuzumab emtansine, and Enfortumab … Read more
Since 2000, the ADC field has gradually started to be pushed to market, and in recent years, it has emerged rapidly in the field of cancer treatment, leading to intense competition. To differentiate themselves, some companies are beginning to develop ADCs for non-oncology areas. Although the number of related ADCs is extremely limited and most … Read more
Antibody-drug conjugates (ADCs) are formed by linking monoclonal antibodies (mAbs) with small molecule drugs through linkers. The specificity of mAbs for tumor cells allows small molecule drugs to act effectively within tumor tissues, significantly reducing the high toxic side effects of traditional small molecule drugs and enhancing overall therapeutic efficiency. Currently, there are 13 ADC … Read more
The purpose of this article is to introduce the theory and knowledge related to high-speed ADCs, detailing sampling theory, data sheet specifications, ADC selection criteria and evaluation methods, clock jitter, and other general system-level considerations. Additionally, some users hope to further enhance the performance of ADCs through techniques such as interleaving, averaging, or dithering. 1. … Read more
ADC drug conjugation refers to the method of linking various components of ADC, which determines the drug-antibody conjugation ratio (DAR) and homogeneity, affecting the drug’s activity, tolerance, and stability. It is generally divided into random coupling and site-specific coupling. Non-Site-Specific Coupling Common methods include coupling at Lys residues and Cys residues. Site-Specific Coupling, which includes … Read more